2011•中華民國大腸直腸外科醫學會雜誌Requires access
No Definite Benefit of 5-FU/LV Chemotherapy in Patient with Stage IIIColorectal Cancer but Only One Lymph Node Metastasis
Shang-Chiung Wang, Shu‐Wen Jao, Chang‐Chieh Wu, Chia‐Cheng Lee, Tsai‐Yu Lee, Cheng-Wen Hsiao, Jen‐Kou Lin, Tzu‐Chen Lin, Wei-Chone Chen, Jeng‐Kai Jiang, Shung‐Haur Yang, Huann‐Sheng Wang, Shih‐Ching Chang
Open publisher page 0 citations
Abstract
Purpose. Adjuvant chemotherapy can reduce mortality and recurrence of patients with stage III colorectal cancer (CRC). The purpose of this study is to evaluate efficacy of chemotherapy in patients with stage III colorectal cancer accompanied with solitary lymph node metastasis.Method. A total of 405 patients with stage III colorectal cancer and only one lymph node metastasis, who underwent surgery in Tri-Service General Hospital and Taipei Veterans General Hospital from February 27th, 1990, to September 18th, 2006, were enrolled. The patients with the number of total examined lymph nodes less than 12 were excluded. The 5-year overall survival rate and 5-year disease free survival rate were analyzed.Results. The number of patients with and without 5-FU/LV adjuvant chemotherapy was 186 and 219, respectively. Comparing the two groups, those younger patients tended to receive chemotherapy (p = 0.04). The 5-year overall survival rates in the stage III patients with only one lymph node metastasis, who received and didn’t receive adjuvant chemotherapy, were 65% and 68%, respectively. The 5-year disease free survival rates of the two groups were 59.6% and 57.2% respectively. Both results did not reach statistical significance. (p = 0.576 and p = 0.42)Conclusion. The result showed that 5-FU/LV adjuvant chemotherapy in stage III patients with solitary lymph node metastasis did not affect the 5-year overall survival and 5-year disease free survival. Therefore, applying 5-FU/LV chemotherapy for this group of patients with one lymph node metastasis is controversial.